Introduction
Cardiac resynchronization therapy (CRT) improves functional status and cardiac function and decreases heart failure (HF) hospitalizations and mortality among HF patients with left ventricular systolic dysfunction and QRS prolongation [1] [2] [3] [4] [5] [6] [7] [8] . Initially, CRT was applied to patients with advanced HF, but more recent studies have shown similar benefit among patients with milder HF [9] [10] [11] . The reverse remodeling response, as measured by left ventricular volumetric changes, has important prognostic significance in pharmacologic studies of HF, including randomized studies of angiotensin converting enzyme (ACE) inhibitors 12, 13 , angiotensin receptor blockers (ARB) 14 , beta blockers 15, 16 , and with ivabradine 17 . There are many other studies in support of the beneficial action of pharmacologic agents to induce reverse remodeling in HF 18 .
With regard to CRT, randomized trials showed that reverse remodeling predicts clinical outcomes and arrhythmia events 19, 20 . However, the long-term impact of remodeling on mortality is less well-studied. Accordingly, the present analysis was designed to evaluate changes in left ventricular volume on all-cause mortality in the preplanned 5 year follow-up of the REVERSE Study.
Methods
The design and primary results of the REVERSE trial were published previously 9, 21, 22 . Briefly, Echocardiograms were obtained at baseline (prior to implant) and after 6 months of randomization with CRT turned off temporarily. Data were analyzed in one of two core laboratories (Philadelphia, USA and Pavia, Italy) blinded to clinical data. LV dimensions were recorded with 2D-directed M-mode echocardiography at the tips of the mitral valve leaflets.
Echocardiograms were digitized to obtain LV volumes by Simpson's method of discs, as recommended by the American Society of Echocardiography 26 , from which LVEF was calculated. Change in LV end-systolic volume, indexed by body surface area (LVESVi), was the pre-defined and independently powered secondary endpoint of REVERSE. Additional echocardiographic measures included LV end-diastolic volume index (LVEDVi) and EF.
Further details of the echocardiographic protocol have been published previously 21 .
Patients were actively followed with in-office visits at least every 6 months through 5 years of follow-up, at which time patients were exited. Mortality was assessed during this period and each death was adjudicated by an independent adverse events adjudication committee to classify the cause of death by standard criteria.
For the initial analysis of the effect of LVESVi change on mortality, patients were divided into two groups using the commonly used cutoff of a 15% decrease of volume that was prespecified in REVERSE 19, 21 . Subsequent analyses separated the changes into quartiles or treated LVESVi change as a continuous variable to allow more detailed assessment of the response.
Data Analysis
Continuous 
Results

Patient Population
Of the 610 patients in REVERSE, 419 were randomized to CRT ON. In this group, 66 subjects were not included in the present analysis for the following reasons: six subjects died prior to their 6-month follow-up, 3 subjects missed their 6-month follow-up, and 57 subjects had inadequate echocardiograms for adequate LVESVi measurement at baseline (23), 6 months (24), or both (8) . Thus, there were 353 patients included in the present study. Of note, there were no statistically significant differences (p<0.05) in baseline characteristics between the included and excluded subjects. The 353 patients averaged 4.6 years of implanted follow-up time.
Baseline characteristics of the patient population are presented in Table 1 . This was a typical population of mild HF patients receiving CRT. They were predominately late middle age men with a majority having ischemic heart disease and an underlying left bundle branch block on the unpaced ECG.
Reverse Remodeling
The echocardiographic measures of reverse remodeling were assessed after 6 months of CRT.
LVESVi decreased by an average of 14.9 ± 27.5 ml/m 2 , LVEDVi decreased 15.8 ± 32.4 ml/m 2 , and the EF increased 3.6 ± 8.3% in this cohort. As shown previously, all of these changes were highly significant compared with the unpaced CRT OFF group 9 . The pre-specified remodeling endpoint in this study was a reduction of LVESVi. A reduction of at least 15% was reached by 183 (52%) subjects. There were some important clinical differences between subjects with a > 15% change in LVESVi and those who did not reach this endpoint; these results are shown in Table 1 . Those patients with significant remodeling were more likely to be female, have nonischemic cardiomyopathy, and have a typical left bundle branch block (LBBB). In addition, the unpaced QRS duration was longer.
Survival with CRT
The REVERSE cohort was followed for 5 years as a pre-planned extension phase of the randomized portion of the trial 27 . Such long-term follow-up allows for the assessment of mortality, which was low as expected over the first 1-2 years in patients with mild heart failure [9] [10] [11] . The mortality curves for the subgroups with and without significant reductions in LVESVi are presented in Figure 1 . The curves begin to separate about 15 months after the 6-month follow-up, and they continue to be separate over the full duration of follow-up. The Hazard Ratio is 0.32 (p=0.0004) indicating a 68% lower mortality rate in subjects who achieved the remodeling endpoint (> 15% reduction in LVESVi). It is noteworthy that the estimated longterm mortality was very low (6.9%) in the subgroup with significant remodeling despite severe systolic dysfunction and QRS prolongation at baseline. Table 2 lists the adjudicated causes of death within the two groups. The subgroup achieving the remodeling endpoint had a lower rate of death in all categories, including sudden and non-sudden cardiac death.
Although a decrease of LVESVi > 15% is commonly used to define an echocardiographic remodeling response to CRT, this arbitrary cutoff could affect the results. Therefore, the response was subdivided in quartiles to evaluate the effect on remodeling more accurately. The largest remodeling response (quartile 4) was a > 32.1% reduction of LVESVi, whereas patients with an increase of LVESVi despite CRT constituted quartile 1. These results are shown in Figure 2 . There was again a very significant effect of change of LVESVi on mortality (p<0.0001) with the lowest mortality among subjects with the largest reduction and a very high mortality among subjects with an increase in LV volume at 6 months.
Current guidelines strongly recommend CRT in mild heart failure only for patients with LBBB 28 \; accordingly, the analysis was repeated in subgroups based on QRS morphology.
These results are presented separately in Figure 3 for the LBBB (n=217) and non-LBBB (n=133)
cohorts. The p-values within both groups were significant indicating that change in LVESVi is a significant factor in predicting future mortality in both LBBB and non-LBBB patients.
As noted previously, there were some important clinical differences between the subjects in the different remodeling subgroups, so a multi-variable analysis was performed. For this analysis, the change in LVESVi was treated as a continuous variable. These results are shown in Table 3 . After adjusting for important covariates, remodeling was a strong independent predictor 
Discussion
The primary result of the present analysis is that the change in LVESVi with CRT was a strong independent predictor of long-term mortality in mild HF. Specifically, among subjects with a > 15% reduction of LVESVi after 6-months of CRT, all-cause mortality was 1.6% annually. This was a 68% lower mortality relative with the rest of the cohort. A more detailed analysis of response identified a very high risk cohort with further LV dilation with CRT, which constituted about 25% of the population. Mortality was more than 4-fold greater in this subgroup (29.8% vs 6.9% for > 15% reduction of LVESVi). Finally, the magnitude of other echocardiographic measures of remodeling (LVEDVi and EF) also showed strong relationships with long term survival.
The impact of LV volumetric changes on mortality has been assessed previously in both pharmacologic and CRT studies. In SOLVD Treatment, subjects receiving enalapril had a mean CRT and betablockers are linked to the greatest magnitude of left ventricular reverse remodeling compared to other heart failure drug therapies 18 . More than 95% of patients in more recent randomized clinical trials of CRT have been on betablockers [10] [11] [12] . Reverse remodeling by beta blockade is dependent on dose 15 . In REVERSE, 60% were on at least 50% of guidelineindicated dose and 30% on target dose 31 . As CRT can be used as further therapy in addition to beta blockade, this combination may be the most potent in terms of reverse remodeling which is reflected in our results. To our knowledge, REVERSE is the first study to show that reverse remodeling by a non-pharmacological HF therapy is an independent predictor of long term survival.
With regard to previous studies of CRT, several studies demonstrated a relationship between remodeling and composite endpoints including survival. Ypenburg et al 26 reported a relationship between the extent of LV volume changes and mortality and heart failure hospitalizations.
Similarly, Yu et al 27 showed that a reduction in LVESV of 10% significantly lowers the risk of mortality and heart failure events. Finally, analysis of the MADIT CRT study showed a reduction of the composite endpoint of HF hospitalization and survival in both the CRT and ICD groups 29 . The present results suggest that large reductions of LVESVi are associated with decreases of both non-sudden and sudden death. The impact of reverse remodeling on HF mortality is not surprising given the associations of remodeling with reductions of HF hospitalization noted above. LV volumetric changes have also been shown to decrease ventricular arrhythmia in both the REVERSE 19 and MADIT CRT 35 studies, so again it follows that a reduction of sudden death may be expected long term. There was also an apparent decrease in non-cardiac death. Whether this was due to the identification of a sicker subgroup of patients more prone to die from the sequela of HF, such as renal failure or infection, or to mortality classification difficulties cannot be determined from these results.
The impact of reverse remodeling on long term mortality was noted for the non-LBBB subgroups. This is particularly interesting, as current guidelines do not recommend CRT for these patients with mild HF on the results of large randomized trials 10, 11 . The remodeling response is much smaller in non-LBBB subjects [36] [37] [38] , which is consistent with poorer outcomes.
However, the present results indicate improved survival in those subjects who have a significant decrease in LVESVi with CRT. Further study is needed to assess if there are predictors of a good remodeling response in the non-LBBB cohort who may benefit from CRT.
There are several clinical implications of these data. First, the present findings confirm that echocardiographic measures of remodeling are an important endpoint for CRT response. Such responses at 6 months are a strong predictor of mortality, so this should be considered as an endpoint for studies designed to optimize CRT, as it would save considerable sample size and time over studies using mortality as an endpoint. Second is the observation that further LV dilation despite CRT is a very poor prognostic sign with a high mortality. These patients should be considered for intervention including alternative advanced heart failure therapy optimization of programming parameters, lead repositioning or even discontinuation of CRT. Finally, the clinical predictors of long term mortality with CRT are very similar to the predictors of clinical response in mild HF [9] [10] [11] [35] [36] [37] . Specifically, in addition to the change of LVESVi, women, increased unpaced QRS duration, CRT-D devices, and smaller LV volumes were associated with lower mortality. CRT-D had been previously shown to be associated with reduced mortality 39 , while the other factors were shown to be associated with reduced HF hospitalizations [9] [10] [11] .
This study should be interpreted in the face of several methodological limitations. The REVERSE study was double-blinded only during the randomized phase including the echocardiographic assessment. It is conceivable that this affected treatment at different phases of the study. In addition, titration of medications was discouraged during the randomized phase and this may affect long-term outcome. Finally, this study only evaluated subjects with mild HF.
Conclusions
In summary, in the long-term follow-up of REVERSE patients with CRT, reverse remodeling, as defined as a > 15% reduction of LVESVi was associated with a 68% mortality reduction.
Analysis adjusting for baseline covariates showed a 14% reduction in mortality for every 10% change in LVESVi. Finally, the subgroup of patients who continue to remodel despite CRT (LVESVi increases) have a markedly increased mortality. 
Clinical Perspective
Pharmacologic therapies for systolic heart failure (HF) that are associated with reverse left ventricular remodeling produce a mortality benefit. In the present study, the long term effect of reverse remodeling on mortality with cardiac resynchronization therapy (CRT) was assessed. A 15% or greater reduction of LVESVi, which is the standard measure of remodeling with CRT, was associated with a 68% all-cause mortality reduction. Similar results were observed with other remodeling parameters, including a reduction of LVEDVi or an increase of ejection fraction. Equally important, the subgroup of patients who continue to remodel despite CRT have a markedly increased mortality. These findings indicate that reverse remodeling should be a goal of CRT therapy and is an appropriate short term (6 months) endpoint for interventions to optimize this treatment. Such interventions include physiologic measures to optimize LV lead position or programmed pacing parameters. However, continued LV dilation with CRT is a marker of a poor prognosis and warrants aggressive treatment, such as alternative HF therapies or considering inhibiting CRT. 
